Business Wire

Theramex Announces European Commission Marketing Authorization for Yselty® (linzagolix), an Oral GnRH Antagonist, for the Treatment of Symptoms of Uterine Fibroids

Share

TheEuropean Commission (EC) has granted Marketing Authorization for Yselty® (linzagolix), an oral GnRH antagonist, indicated for the treatment of moderate to severe symptoms of Uterine Fibroids (UF) in adult women (over 18 years of age) of reproductive age. This announcement is in partnership with ObsEva SA (Nasdaq: OBSV), a biopharmaceutical company developing and commercializing novel therapies for women’s health.

The EC decision follows the Committee for Medicinal Products for Human Use (CHMP) confirmation of positive opinion in April 2022.

Linzagolix ® is the only approved oral GnRH antagonist to offer flexible dosing options, with and without additional hormonal therapy, for women suffering from UF. Yselty® is approved in the EU at the following doses:

  • 100 mg or 200 mg once daily with hormonal ABT, with no limitation in treatment duration
  • 100 mg once daily for women in whom ABT is not recommended or who prefer to avoid hormonal therapy, with no limitation in treatment duration
  • 200 mg once daily for short-term use (< 6 months) in clinical situations when reduction of uterine and fibroid volume is desired

The approval is based on positive data from the ObsEva’s two Phase 3 PRIMROSE trials.

“Uterine Fibroids affect 25% of women within reproductive age, many with severe symptoms requiring surgery. With the approval of Linzagolix we can potentially offer a new treatment option for physicians in managing women with uterine fibroids to provide symptomatic relief and delay or avoid surgery. Additionally, we will continue to work with our partner ObsEva for follow-on indications, such as endometriosis, another area of women’s health with limited treatment options. This marks an important therapeutic extension for Theramex to widen our portfolio and provide gynaecologist’s support for unmet medical needs,” said Robert Stewart, Theramex CEO.

“As the first and only approved GnRH antagonist to provide flexible dosing options with and without hormonal add-back therapy, Yselty® has the potential to transform the treatment paradigm and significantly advance medical options for women in the EU with uterine fibroids,” said Dr. Brandi Howard, Chief Clinical Officer of ObsEva. “We are pleased to be the first to provide women and doctors with a non-hormonal dosing option for the millions of women who either have contraindications to or a personal preference to avoid the use of hormonal add-back therapy, while also providing dosing options for women for whom hormonal add-back therapy is appropriate.”

In February 2022, Theramex entered into a strategic licensing agreement with Obseva, a leading biopharmaceutical company in novel therapies, to commercialize and market the introduction of linzagolix across international markets outside of the U.S., Canada, and Asia.

About Yselty® (linzagolix)

Linzagolix is a once daily, oral GnRH receptor antagonist developed to offer flexible dosing options with and without hormonal add-back therapy to women suffering from uterine fibroids and is approved in the EU.

About Theramex

Theramex is a leading global speciality pharmaceutical company dedicated to women and their health. Theramex supports women at different stages of their lives by providing a broad portfolio of innovative and established brands covering contraception, fertility, menopause and osteoporosis. Theramex’s commitment is to listen to and understand its patients, serve their needs and offer healthcare solutions to help improve their lives. Theramex’s vision is to be a lifetime partner for women and the healthcare professionals who treat them by providing patient-focused and effective solutions that care for and support women through different stages of their life.

About ObsEva

ObsEva is a biopharmaceutical company developing and commercializing novel therapies to help improve women’s reproductive health and pregnancy. The Company’s first approved drug is Yselty® (linzagolix), which is approved in the EU. ObsEva is listed on the Nasdaq Global Select Market and is traded under the ticker symbol “OBSV” and on the SIX Swiss Exchange where it is traded under the ticker symbol “OBSN”.

For more information, please visit www.ObsEva.com

About Kissei

Linzagolix has been discovered by Central Research Laboratories of Kissei Pharmaceutical Co., Ltd. Kissei is a Japanese pharmaceutical company based on the management philosophy “contributing to society through high-quality, innovative pharmaceutical products” and “serving society through our employees.” As a strong R&D-oriented corporation, it concentrates on providing innovative pharmaceuticals to patients worldwide in the focus fields of urology, nephrology/dialysis, gynaecology and rare/intractable diseases.

Yselty_HQ_PRESSR_007649 D.O.P: 17/06/22

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For further information, please contact:
Camilla Harder Hartvig
CommunicationsPR@Theramex.com
+44 203 962 5555

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Travelex Bank Selects ThetaRay for Transaction Monitoring and Sanctions Screening6.7.2022 14:00:00 CEST | Press release

ThetaRay, a leading provider of AI-powered transaction monitoring technology, today announced that Travelex Bank, Brazil’s largest foreign exchange specialist, will implement ThetaRay’s SONAR anti-money laundering (AML) SaaS solution for both domestic and international transaction monitoring, as well as real-time sanctions screening for its international payments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220706005020/en/ Travelex Exchange Service (Photo: Business Wire) Travelex Bank is one of the world’s leading specialist providers of foreign exchange, offering a range of international money transfer products including import/export, remittances and mass payments. SONAR will empower Travelex Bank to detect attempts to launder money or circumvent financial sanctions through its system, bringing trust and confidence to all parties in the global payments ecosystem. Additionally, SONAR will allow the company to roll out n

BigCommerce utvider det globale avtrykket til Danmark, Norge, Sverige og Østerrike for å gi selgere mulighet til å skalere og få nettbutikkene sine til å vokse6.7.2022 14:00:00 CEST | Pressemelding

BigCommerce (Nasdaq: BIGC), en ledende åpen SaaS netthandelsplattform for raskt voksende og etablerte B2C- og B2B-varemerker, kunngjorde i dag at de har utvidet deres europeiske tilstedeværelse til Østerrike, Danmark, Norge og Sverige. Med sin DACH og nordiske ekspansjon og fullt lokaliserte teknologi- og byråpartner-økosystem, vil BigCommerce gjøre det mulig for selgere i alle størrelser og kompleksiteter å bygge og skalere nettbedriftene sine for å gi sømløse handleopplevelser til lokale og internasjonale kunder og øke inntektene. "BigCommerces nye tilstedeværelse i DACH og nordiske markeder gir en lokalisert, kraftig og skalerbar åpen SaaS netthandelsplattform til selgere i disse regionene som ikke tidligere har blitt tilbudt disse kjerneprinsippene i én løsning," sa Jim Herbert, senior visepresident og daglig leder EMEA hos BigCommerce. «Med vår velprøvde netthandelsplattform i enterprise-grad, vil selgere av alle typer ha de gode verktøyene og innovative funksjonalitetene – fra he

KBI Biopharma and Selexis Hold Joint Ribbon Cutting of the Expanded State-of-the-Art Facility in Geneva, Switzerland6.7.2022 13:45:00 CEST | Press release

KBI Biopharma SA (KBI) and Selexis SA, both JSR Life Sciences companies, held a joint ribbon-cutting ceremony yesterday at their new state-of-the-art facility in Geneva, Switzerland. Designed to directly serve the increased demand for biopharmaceutical drug development and manufacturing in Europe, the facility will support an integrated, end-to-end process of Selexis’ cell line development (CLD) services along with KBI’s contract development and manufacturing services for industry clients throughout the immediate region and beyond. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220706005082/en/ KBI Biopharma and Selexis ribbon cutting at their new state-of-the-art facility in Geneva, Switzerland, Tuesday, July 5, 2022 (from left to right: Mark Lutgen, KBI Biopharma, VP of Global Engineering; Mario Rodriguez, Mayor, Plan-les-Ouates; Fabienne Fischer, State Councilor and Head of the Department of the Economy and Employment; Ma

ADVA Optical Networking SE: Approval of public exchange offer of Acorn HoldCo, Inc. by German Federal Ministry of Economics and Climate Protection6.7.2022 12:45:00 CEST | Press release

Today, the German Federal Ministry for Economics and Climate Protection (“BMWK”) has granted the foreign direct investment approval that was required for closing the public exchange offer made by ADTRAN Inc.’s subsidiary, Acorn HoldCo, Inc. (“Acorn HoldCo”). With the foreign direct investment approval by the BMWK, all offer conditions for Acorn HoldCo’s public exchange offer published on 12 November 2021 are fulfilled. The settlement of the exchange offer is expected by 15 July 2022, but at the latest on 18 July 2022. Acorn HoldCo’s shares will be admitted to trading on NASDAQ and the Frankfurt Stock Exchange. Disclaimer To the extent any announcements in this document contain forward-looking statements, such statements do not represent facts and are characterized by the words "will", "expect", "believe", "estimate", "intend", "aim", "assume" or similar expressions. Such statements express the intentions, opinions or current expectations and assumptions of ADVA and the persons acting j

GlobalLogic Achieves Green Sustainability Ranking via the NQC SupplierAssurance Platform6.7.2022 12:00:00 CEST | Press release

GlobalLogic Inc., a Hitachi Group company and a leader in Digital Engineering, today announced it has achieved a Green rating via the NQC SupplierAssurance platform—a cloud-based solution used by suppliers to determine their sustainability performance level. Based on the Self-Assessment Questionnaire (SAQ 4.0) and validated by the NQC Supplier Assurance Team for accuracy, the results show GlobalLogic earning a score of 72% in its market category of Engineering and Research Technology Based Services. That score is significantly higher than the category average of 47% across more than 1200 locations. The automotive industry in particular has increased its focus on green initiatives. Stringent regulations and standards requiring substantial improvements to automotive manufacturing practices and direct environmental impact have been implemented in various regions. Examples range from the European Commission’s EU 2019/631 regulation targeting vehicle CO2 emissions to numerous ISO standards